title: [Clinical effectiveness of INSURE method in the treatment of neonatal respiratory distress syndrome].
abstract: OBJECTIVE
  To evaluate the clinical effectiveness and safety of intubation-surfactant-extubation (INSURE) method in the treatment of neonatal respiratory distress syndrome (NRDS), and to investigate its possible mechanisms.
  
  
  METHODS
  Sixty-four premature infants, who were admitted for NRDS and treated with pulmonary surfactant from March 2010 to March 2012, were enrolled in the study. They were randomly divided into INSURE (n=32) and conventional mechanical ventilation (CMV) groups (n=32). The two groups were compared in terms of respiratory function, ventilation time, duration of oxygen therapy, complications, and prognosis, as well as expression of interleukin-10 (IL-10), tumor necrosis factor-α (TNF-α) and serum ferritin (SF).
  
  
  RESULTS
  Oxygenation index in the INSURE group was significantly higher than in the CMV group at 48 hours after treatment (P<0.05). Compared with the CMV group, the INSURE group showed significantly lower incidence of ventilator-associated pneumonia (VAP) and significantly shorter duration of oxygen therapy (P<0.05 for all comparisons). There were no significant differences in ventilation time and the incidence of pneumothorax, intracranial hemorrhage, necrotizing enteroolitis, bronchopulmonary dysplasia, and pneumorrhagia between the two groups (P>0.05). The levels of TNF-α and SF were significantly lower in the INSURE group than in the CMV group at 6, 24, 48, and 72 hours after treatment (P<0.05), while the level of IL-10 was significantly higher in the INSURE group than in the CMV group (P<0.05).
  
  
  CONCLUSIONS
  INSURE method can improve the oxygenation function of the lung, decrease the incidence of VAP and shorten the duration of oxygen therapy in neonates with NRDS, which is probably due to the fact that this method can reduce the production of TNF-α and SF and inhibit the decrease of IL-10.
authors: Department of Neonatology, Shaoyang Central Hospital, Shaoyang, Hunan, China. hx16311@163.com
authors: Xi-Lin
authors: XL
authors: Huang
authors: Dan
authors: D
authors: Chen
authors: Xiao-Ping
authors: XP
authors: Li
authors: Ming-Yu
authors: MY
authors: Li
authors: Jian-Feng
authors: JF
authors: Shen
authors: Xiao-Song
authors: XS
authors: Wu
mesh_terms: D002245:Carbon Dioxide / Q000097:blood; D005260:Female; D005293:Ferritins / Q000097:blood; D006801:Humans; D007231:Infant, Newborn; D016753:Interleukin-10 / Q000097:blood; D008297:Male; D012121:Respiration, Artificial; D012127:Respiratory Distress Syndrome, Newborn / Q000097:blood / Q000628:therapy*; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
chemical_list: D014409:Tumor Necrosis Factor-alpha; D016753:Interleukin-10; D002245:Carbon Dioxide; D005293:Ferritins